TrialLancet (London, England)2017

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).

Krishnansu S Tewari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.